Accessibility Menu
Tempest Therapeutics logo

Tempest Therapeutics(NASDAQ) TPST

Market Cap$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-99%
1 Year-89%
1 Month+26%
$1.10
+4.76%
+0.05Today
After hours$1.10+$0.00 (+0.00%)
Tempest Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.102026-09-02
Tempest Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.85%USD 1.082026-08-26
1 month+25.7%USD 0.882026-08-03
3 month-15.38%USD 1.302026-06-04
Year to date-61.67%USD 2.872025-12-31
1 year-89.18%USD 10.172025-09-02
3 year-84.33%USD 7.022023-09-01
5 year-99.43%USD 193.572021-09-03
Since inception-99.37%USD 173.682021-06-28

Tempest Therapeutics Financials at a Glance

Market Cap

$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.47M

EPS (TTM)

-$4.48

P/E Ratio

-0.25

Dividend

$0.00

Beta (Volatility)

1.64 (High)

Price

$1.10

Volume

31,440

Open

$1.05

Previous Close

$1.10

Daily Range

$1.05 - $1.12

52-Week Range

$0.84 - $12.23

Estimated Earnings Date

Nov 4, 2026

TPST News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tempest Therapeutics

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapies for cancer treatment. The company is advancing several novel product candidates aimed at introducing first-in-class solutions for various cancers. Tempest's lead program, TPST-1120, is moving toward pivotal studies targeting liver cancer, showcasing promising results in early phase trials.

Products and Services

TPST-1120: A small molecule inhibitor targeting a cancer-promoting transcription factor, with ongoing trials in liver cancer.

TPST-1495: Dual antagonist of specific prostaglandin receptors with clinical trials underway for endometrial cancer and research directed toward additional indications.

What Makes Tempest Therapeutics, Inc. Special

Tempest's unique approach is centered on small-molecule therapeutics designed to modulate vital cancer pathways. This innovation underlies a diversified pipeline and opens possibilities for combination strategies with existing oncology treatments. The leadership team's expertise in oncology enhances the company's ability to progress its ambitious clinical strategies.

Five Things You Need to Know

Current clinical programs target liver and endometrial cancers with potential expansion to other cancer types.

TPST-1120 shows a significant objective response rate in liver cancer relative to standard treatments.

Collaborative efforts, notably with Roche, are crucial for global clinical study operations.

Tempest possesses worldwide rights to its leading product candidates, offering robust patent protection.

Future plans include pursuing strategic alliances to expand research capabilities and market reach.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Matthew Angel, Ph.D

Website

www.tempesttx.com

Headquarters

Brisbane, CA 94005, US

TPST Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1270.11%

Return on Capital

-179.45%

Return on Assets

-420.14%

Earnings Yield

-4.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.98M

Volume

31.44K

Avg. Volume

204.32K

Financials (TTM)

Gross Profit

-$22.18M

Operating Income

-$40.64M

EBITDA

-$40.29M

Operating Cash Flow

-$20.73M

Capital Expenditure

$0.00

Free Cash Flow

-$20.73M

Cash & ST Invst.

$779.00K

Total Debt

$7.56M

Tempest Therapeutics Performance Analysis

Tempest Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tempest Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Tempest Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -40.20-58.6%
20232023-12-31USD -24.87-38.1%
20242024-12-31USD -19.50-21.6%
20252025-12-31USD -6.33-67.5%
Tempest Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3061.8%
Q42025-12-31-3.8%
Q12026-03-31-208.5%
Q22026-06-3086.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$17.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.39M

N/A

Employees

4

N/A

Net Income

-$5.24M

+33.4%

EBITDA

-$5.25M

+32.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$779.00K

-94.5%

Total Debt

$7.56M

-12.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$6.27M

-17.0%

Short Term Debt

$1.29M

+16.7%

Return on Assets

-4.20%

N/A

Return on Invested Capital

-7.84%

N/A

Free Cash Flow

-$2.78M

+67.0%

Operating Cash Flow

-$2.78M

+67.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PDSBPDS Biotechnology Corporation
$0.21+3.92%
BRNSBarinthus Biotherapeutics plc
$0.74-2.88%
FGENFibroGen, Inc.
$9.07-1.63%
ALGSAligos Therapeutics, Inc.
$6.21+1.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$51.83-0.01%
BIAFbioAffinity Technologies
$9.75+0.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$106.35+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.60+0.01%

Questions About TPST

What is the current price of Tempest Therapeutics?

Tempest Therapeutics is trading at $1.10 per share.

What is the 52-week range for Tempest Therapeutics?

Over the past 52 weeks, Tempest Therapeutics has traded between $0.84 and $12.23.

How much debt does Tempest Therapeutics have?

As of the most recent reporting period, Tempest Therapeutics reported total debt of $7.56M.

How much cash does Tempest Therapeutics have on hand?

Tempest Therapeutics reported $779.00K in cash and cash equivalents in its most recent financial results.

What is Tempest Therapeutics’s dividend yield?

Tempest Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services